IBRN
iShares Neuroscience and Healthcare ETF
IBRN tracks a market cap-weighted index that provides global equity exposure to companies that are positioned to benefit from neuroscience advancements. The index may hold securities from large- to small-cap.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 5.4 M
ASSETS UNDER MGMT
47 bp
EXPENSES
Fund Basics
| Inception date | Aug 24, 2022 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Semi-annual |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| AXSOME THERAPEUTICS, INC. | 4.8 % |
| XENON PHARMACEUTICALS INC | 4.6 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 4.6 % |
| ALKERMES PLC | 4.4 % |
| NEUROCRINE BIOSCIENCES INC | 4.1 % |
| ARGENX SE ADR | 3.9 % |
| CENTESSA PHARMACEUTICALS AMERICAN | 3.8 % |
| PRAXIS PRECISION MEDICINES INC | 3.7 % |
| BIOGEN IDEC INC | 3.7 % |
| PTC THERAPEUTICS INC | 3.6 % |
Constituent Breakdown
| Number of holdings | 73 |
| Herfindahl-Hirschman Index | 293 |
| Wgt avg mkt cap (mns) | $5,638 |
| Large cap (>$10bn) | 11.7% |
| Mid cap ($2-10bn) | 40.8% |
| Small cap (<$2bn) | 19.8% |
| Developed mkts. | 75.6% |
| Emerging mkts. | 2.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 64.5 % |
 |
IRELAND | 4.9 % |
 |
NETHERLANDS | 3.9 % |
 |
SOUTH KOREA | 2.0 % |
 |
SWITZERLAND | 1.1 % |
 |
JAPAN | 0.8 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 10.9% | 63.2% | 23.3% | 14.0% | -- | -- | -- | 10.6% |
| Dividend Yield | 0.0% | 1.6% | 0.8% | 0.5% | -- | -- | -- | 0.4% |
| Total Returns | 10.9% | 64.8% | 24.2% | 14.5% | -- | -- | -- | 11.0% | Ann. Volatility | 27.2% | 25.0% | 26.0% | 24.7% | -- | -- | -- | 25.2% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.25 | 35% |
| MSCI EAFE | 0.98 | 35% |
| MSCI Emg Mkts | 0.66 | 27% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.7% |
| Avg. Bid/Ask (% of price) | 0.40% |
Technical Indicators
| 30d moving avg. (EMA) | $34.79 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.28/0.27 |
| Bollinger Bands (Upper/Lower) | $36.51/$33.85 |
| Short interest (% of AUM) | 4.9% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IBRN |
Expenses vs. IBRN |
ALTAR Score™ vs. IBRN |
|---|---|---|---|---|
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 24.5% | +9 bp | +1.8% |
| SBIO | ALPS Medical Breakthroughs ETF | 17.9% | +3 bp | 0.0% |
| PBE | Invesco Biotechnology & Genome ETF | 16.6% | +11 bp | +3.0% |
| XBI | State Street SPDR S&P Biotech ETF | 14.9% | -12 bp | -0.1% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 13.2% | -18 bp | +2.7% |
| IBB | iShares Biotechnology ETF | 12.8% | -2 bp | -0.6% |
| PSIL | AdvisorShares Psychedelics ETF | 12.6% | +52 bp | -1.3% |
| BBP | Virtus LifeSci Biotech Products ETF | 11.3% | +32 bp | -3.8% |
Risk and Returns: IBRN vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/30/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 728 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. IBRN's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places IBRN in the percentile
among funds in the category.
Sell-Side Consensus
$43.54
PRICE TARGET
+21.5%
UPSIDE